Co-administration of probenecid, an inhibitor of a cMOAT/MRP-like plasma membrane ATPase, greatly enhanced the efficacy of a new 10-deazaaminopterin against human solid tumors in vivo

Clinical Cancer Research

Volumn 6, Issue 9, 2000, Pages 3705-3712

  Sirotnak, F M ^a   Wendel, H G ^a   Bornmann, W G B ^a   Tong, W P ^a   Miller, V A ^a   Scher, H I ^a   Kris, M G ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

10 DEAZAAMINOPTERIN; ADENOSINE TRIPHOSPHATASE INHIBITOR; FOLIC ACID DERIVATIVE; PROBENECID;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DRUG POTENTIATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SOLID TUMOR;

ADENOSINE TRIPHOSPHATASES; AMINOPTERIN; ANIMALS; ANION TRANSPORT PROTEINS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ATP-BINDING CASSETTE TRANSPORTERS; CARRIER PROTEINS; CELL MEMBRANE; DRUG SYNERGISM; ENZYME INHIBITORS; FOLIC ACID ANTAGONISTS; HUMANS; MICE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASMS, EXPERIMENTAL; PROBENECID; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0033813261     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Obligate genetic expressing in tumor cells of a fetal membrane property mediating folate transport: Biological significance and implications for improved therapy of human cancer
2. The cellular pharmacology of methotrexate
3. A novel cDNA restores reduced folate carder activity and methotrexate sensitivity to transport deficient cells
4. Isolation of a hamster cDNA clone coding for a function involved in methotrexate uptake
5. Isolation of human cDNAs that restore methotrexate sensitivity and reduced folate carrier activity in methotrexate transport-defective Chinese hamster ovary cells
6. Isolation of a human cDNA that complements a mutant hamster cell defective in methotrexate uptake
7. Molecular cloning of the human placental folate transporter
8. Isolation of a gene encoding a human reduced folate carrier (RFCI) and analysis of its expression in transport-deficient, methotrexate-resistant human breast cancer cells
9. Antifolate transport in L1210 leukemia cells. Kinetic evidence for the non-identity of carriers for influx and efflux
10. Effects of metabolic deprivation on methotrexate transport in L1210 leukemia cells: Further evidence for separate influx and efflux systems with different energetic requirements
11. Transport routes utilized by L1210 cells for the influx and efflux of methotrexate
12. The issues of transplant multiplicity and energetics pertaining to methotrexate efflux in L1210 cells addressed by an analysis of cis and trans effects of inhibitors
13. Energy dependent efflux of methotrexate in L1210 leukemia cells. Evidence for the role of an ATPase obtained with inside-out plasma membrane vesicles
14. ATP-dependent efflux of 2,4-dinitro phenyl-S-glutathione. Properties of two distinct transport systems in inside-out vesicles from L1210 cells and a variant subline with altered efflux of methotrexate and cholate
15. Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance associated protein gene (MRP1) in human cancer cell lines
16. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line
17. MOAT-4, a novel multispecific organic-anion transporter for glucuronides and mercapturates in mouse L1210 cells and human erythrocytes
18. Isolation of MOAT-B, a widely expressed multidrug resistance-associated protein/canicular multispecific organic anion transporter-related transporter
19. Expression of human MRP6, a homologue of the multidrug resistance protein MRP1, in tissues and cancer cells
20. Methotrexate is excreted in the bile by canicular multispecific organic anion transporter in rats
21. Expression of multidrug resistance protein 3 (multispecific organic transporter-b) in human embryonic kidney 293 cells confers resistance to anticancer agents
22. Characterization of MOAT-C and MOAT-D, new members of the MRP/cMOAT subfamily of transport proteins
23. Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2
24. cDNA cloning of a short type of multidrug resistance protein homologue. SMRP, from a human lung cancer cell line
25. The multidrug resistance protein family
26. Isolation of a new transporter gene from human small intestine
27. Expression of Mrp-4 (MOAT-B) in NIH3T3 cells confers resistance to methotrexate and the anti-AIDS drug PMEA
28. Increased accumulation of methotrexate by murine tumor cells in vitro in the presence of probenecid which is mediated by a preferal inhibition of efflux
29. Improved methotrexate therapy of murine tumors obtained by probenecid-mediated pharmacological modulation at the level of membrane transport
30. A new analogue of 10-deazaaminopterin with markedly enhanced curative effects against human tumor xenografts in mice
31. Similar differential for total polyglutamylation and cytotoxicity among various folate analogues in human and murine tumor cells in vitro
32. Correlates of folate analog transport, pharmacokinetics and selective antitumor action
33. Fluorometic HPLC analysis of 10-deazaaminopterin, 10-ethyl-10-deazaaminopterin and known metabolites
34. Folate analogs of the 10-deaza-aminopterin series. Basis for structural design and biochemical and pharmacologic properties
35. Selective antitumor action of folate analogues
36. Structural preferences among folate compounds and their analogues for ATPase-mediated efflux by inside-out plasma membrane vesicles derived from L1210 cells
37. Prolongation and enhancement of serum methotrexate concentrations by probenecid
38. Clinical pharmacology of oral intermediate-dose methotrexate with or without probenecid